| This week's sponsor is Catalent. | | | [Fact Sheet] Biologics Device Assembly & Packaging
Catalent’s biologics packaging operations in the US and Belgium offer state-of-the-art, high-speed, automated equipment, as well as configurable packaging solutions to support both clinical and commercial supply. Learn more about Catalent’s device assembly and packaging capabilities for biologics. |
| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Tuesday, February 12, 2019 A phase 3 trial of Gilead’s NASH prospect selonsertib has bombed. The ASK1 inhibitor was no better than placebo at improving fibrosis, wiping out hopes that selonsertib would spearhead Gilead’s push into a new market. |
|
|
| This week's sponsor is Camargo. | | | [Webinar] Maximizing the Value of Your Drug Development Program
Thursday, February 21 | 11am ET / 8am PT
This webinar will benefit executives at Biotech and Pharmaceutical companies interested in learning more about 505(b)(2) drug development and how to save time and money while maximizing the value of their drug development program. Register Now! |
Top Stories Of The Week Monday, February 11, 2019 These are the ideas that can move the needle. FierceMedTech’s Fierce 15 class of 2018 is aimed at advancement—whether it’s simply combining new know-how with old methods, making definitive improvements in well-trodden fields, or pushing us to reconsider how far we can reach with the means available today. Friday, February 8, 2019 The global recall of valsartan has now extended to Pfizer and to Japan, via Mylan and India. Pfizer’s Tokyo-based subsidiary said it is recalling from the country five lots of its blood pressure combination drug Amubaro because its API contains impurities that are probable carcinogens. Tuesday, February 12, 2019 When Bristol-Myers Squibb picked up Celgene in one of biopharma’s biggest deals ever last month, investors tagged one big risk: Celgene’s megablockbuster Revlimid faced patent challenges that could take a big bite out of sales. But now, the $9.7 billion multiple myeloma therapy has dodged one of those threats. Tuesday, February 12, 2019 Bristol-Myers Squibb investors have been dreading positive kidney cancer results from archrival Merck for months. And now that they’re here, they might do even more damage to Bristol-Myers’ market share than some industry watchers expected. Tuesday, February 12, 2019 Nektar has had a mixed few months as data fed through for its lead cancer drug NKTR-214, but new data in bladder cancer should help steady the ship longer term. Wednesday, February 13, 2019 Johnson & Johnson is diving deeper into robotic surgery with a $3.4 billion agreement to acquire Auris Health, the Silicon Valley designer of endoscopic hardware aimed at lung cancer. The all-cash offer, made through J&J’s Ethicon division, includes additional commitments to milestone payments that could be worth up to $2.35 billion. Thursday, February 7, 2019 After a century of research, there's still no proven way to give protein drugs such as insulin by mouth, which is considered the holy grail of drug delivery. Now, an MIT-Novo Nordisk team has come up with a pill, inspired by the tortoise, that they say could one day replace injections for diabetes patients. Wednesday, February 13, 2019 It's another digital chief for Big Pharma, this time at Sanofi. The French drugmaker tapped its CMO, Ameet Nathwani, as its first chief digital officer, combining the two roles just as it aims to join treatments and technology in the marketplace. Wednesday, February 13, 2019 About two years after Astellas and Affinivax joined forces on developing a novel pneumococcal vaccine with eyes on Prevnar 13, the pair has officially entered the clinic and is already using Pfizer's vaccine king as a comparator. Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|
Resources Sponsored by: AlphaSense It’s never been more challenging to stay on top of trends and innovation shaping the future of healthcare. Discover how AI can help competitive intelligence teams achieve more proactive strategies. Sponsored by: Patheon, part of Thermo Fisher Scientific When a biologics company prepares to launch a new product, it must forecast the manufacturing capacity it will need, factoring in its estimate of the size of future sales, the timing of the launch, the dosage of the product, its strategy for building its market and a host of other variables. Sponsored by: Oracle Health Sciences 92% of survey respondents make changes to their RTSM/IRT systems due to study changes. See what else puts a strain on their clinical trials. Download the Research Whitepaper. Sponsored by: Patheon, part of Thermo Fisher Scientific Download this whitepaper to learn more. Sponsored by: The Kinetix Group Explore how the pharma industry can adapt its approach to the changing healthcare marketplace in the era of the Quadruple Aim Sponsored by: Cofactor Genomics Learn how Health Expression Models provide increased sensitivity, specificity, and accuracy for characterizing immune response in solid tumor specimens. Sponsored by: BioAnalytix, Inc. This whitepaper reviews fundamental aspects of HCPs that pertain to biologic drug development and presents current and emerging approaches to HCP analysis. Sponsored by: Veradigm Clinical trials take too long and cost too much—here's what needs to change. Sponsored by: Reprints Desk, Inc. Go from Search to Full-Text Scientific Papers in a Single Click! Sponsored by: Blue Latitude Health This white paper consists of original data and expert interviews. Download it today for exclusive tools, tips and analysis on achieving launch excellence in challenging pharma markets. Sponsored by: DeciBio Consulting With the liquid biopsy market maturing and >80 companies still competing with liquid biopsy offerings, it is crucial for investors to be able to cut through the noise and identify the winners. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. | 